6 Undervalued Pharmaceuticals Stocks for Friday, August 21
Discover the top 6 undervalued Pharmaceuticals stocks for Friday, August 21 based on AAII’s Stock Grades.Michael Rose
Stock Evaluator: Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. HRMY
$39.93
1.10
2.83%
August 19, 2026 4:00:00 PM
EST
Volume: 765,792
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Commentary & Analysis
Is Harmony Biosciences Holdings, Inc. (HRMY) Overvalued?
We dive into why Harmony Biosciences Holdings, Inc. (HRMY) could be considered overvalued on 2026-08-05, based on AAII’s Value Score and Grade.Tudor Pop
What You Need to Know About Harmony Biosciences Holdings, Inc.'s Q3 Earnings
Harmony Biosciences Holdings, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (HRMY) missed or beat analyst's expectations.Jenna Brashear
Why Harmony Biosciences Holdings, Inc.’s (HRMY) Stock Is Up 5.94%
As of Tuesday, August 04, Harmony Biosciences Holdings, Inc.’s HRMY share price has surged by 5.94%, which has investors questioning if this is right time to sell.Michael Rose
3 Undervalued Pharmaceuticals Stocks for Monday, July 20
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, July 20 based on AAII’s Stock Grades.Michael Rose
Financial Summary
| Share Statistics | HRMY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,218.8 | $618.0 | 55% |
|
| Shares Out (Mil) | 58.8 | 44.8 | 51% |
|
| Institutional Ownership | 99.9% | 85.3% | 96% |
|
| Float (Mil) | 52.1 | 47.4 | 48% |
|
| Beta | 0.91 | 0.70 | 55% |
|
| Avg Daily Volume (000s) | 644 | 390 | 62% |
|
| Price Change (52-week) |
4.7% | 68.6% | 49% |
|
| Growth | HRMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 40.3% | 6.7% | 93% |
|
| Net Income (5yr) | 44.5% | (1.6%) | 92% |
|
| EPS (5yr) | 25.3% | 14.9% | 76 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (8.0%) | (14.9%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | $1.468 | $5.222 | $6.686 | |
| Month Ago EPS | $1.224 | $4.498 | $6.020 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $1.224 | $4.393 | $5.581 | |
| Year/Year Chg | 14.7% | 92.7% | 109.7% | |
| Financials | HRMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $960 | $291 | 50% |
|
| Net Income (TTM) (Mil) | $181 | ($11) | 67% |
|
| EPS (TTM) | $3.140 | ($0.700) | 79% |
|
| Operating Cash Flow (TTM) (Mil) | $355 | ($6) | 66% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $5 | 51% |
|
| Long-Term Debt (Q1) (Mil) | $139 | $6 | 47% |
|
| Enterprise Value (Q1) (Mil) | $1,751 | $450 | 47% |
|
| Valuation | HRMY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.22 | 2.78 | 54% |
|
| P/E | 12.3 | 17.4 | 26% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.5 | 1.1 | 23% |
|
| Ratios | HRMY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.4% | 67.0% | 86% |
|
| Net Margin | 18.9% | (2.3%) | 78% |
|
| ROA | 14.6% | (22.4%) | 93% |
|
| ROE | 20.5% | (20.2%) | 80% |
|
| Liabilities to Assets | 27.2% | 32.2% | 19% |
|
| F-Score | 4 | 3 | 34% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Fisher (Philip) Screen
Factors: Value, Growth
A perspective on the evolution of the investment philosophy of a successful money manager who learned from his mistakes.
| Performance Since Inception: | 4.6% |
| +/- S&P 500: | -2.9 |
Passing Stocks
See All 3 Stocks (as of 8/20/2026)
GURU STRATEGY
Magic Formula Screen
Factors: Value, Quality
Joel Greenblatt's investing approach is based on finding companies with high return on investment that are trading for less than they are worth.
| Performance Since Inception: | 6.8% |
| +/- S&P 500: | -0.7 |
GURU STRATEGY
Muhlenkamp Screen
Factors: Value, Quality, Growth
Muhlenkamp uses a bottom-up approach to selecting stocks, but adjusts his benchmarks based upon the broad economic environment.
| Performance Since Inception: | 6.2% |
| +/- S&P 500: | -1.3 |
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
GURU STRATEGY
Rule #1 Investing Screen
Factors: Value, Quality, Growth
Adapted from Phil Town's Rule #1 book, this screen attempts to identify wonderful companies with attractive prices.
| Performance Since Inception: | 8.3% |
| +/- S&P 500: | +0.8 |
